Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s...
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s disease (“AD”) and Parkinson’s disease...
Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...
Annovis Bio (NYSE: ANVS) announced that its President and CEO, Dr. Maria Maccecchini, will speak at the National Institute on Aging’s (NIA) workshop, “Dementia with Lewy Bodies: Filling the Gaps in...
Annovis Bio (NYSE: ANVS) provided a third-quarter update, announcing significant progress in developing its lead drug candidate, buntanetap, for Alzheimer’s disease (“AD”) and Parkinson’s disease...
Annovis Bio (NYSE: ANVS) has appointed Dr. Matthew Peterson as Senior Clinical Scientist, bolstering the team as it approaches pivotal Phase 3 trials for its neurodegenerative disease therapies, including...
Annovis (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”),...